Mili Arora is an Oncology physician affiliated with UC Davis Comprehensive Cancer Center. OpenAlex indexes 37 publications with 466 citations (h-index 12).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2279 45th Street
Sacramento, CA 95817
Telephone
916-734-5959Registry record last updated 24 Jun 2015.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Gilead Sciences, Inc.Program year20251 payment
- AstraZeneca Pharmaceuticals LPProgram year20252 payments
- Gilead Sciences, Inc.Program year20243 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
72.4%Aromatase Inhibitor39.3%Letrozole43%Anastrozole41%Exemestane16%Part D≥32 patientsKinase inhibitor25.9%Lenvima25%Tafinlar21%Ibrance19%Verzenio15%Mekinist11%Cometriq9%Part D<11 patients+ 2 more classes in this area
Nervous system
9.7%Phenothiazine5.2%Prochlorperazine Maleate100%Part D≥12 patientsSNRI2.6%Venlafaxine Hcl Er100%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
9.5%Serotonin-3 Receptor Antagonist5.7%Ondansetron Hcl100%Part D<11 patientsH2 blocker3.8%Famotidine100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
David Gandara, MD
UC Davis Comprehensive Cancer Center
Jonathan Riess, MD
UC Davis Comprehensive Cancer Center
Brian Jonas, MD
UC Davis Comprehensive Cancer Center
Richard Valicenti, MD
UC Davis Comprehensive Cancer Center
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”